Retatrutide: Lilly takes an aesthetic clinic to court

Until 2026, the fight over retatrutide was waged with warning letters to internet sellers. In August it changed scale: the manufacturer itself took an aesthetic clinic to court. Here: the 2026 legal turn and what sources say about clinics that administer it (the trial data are in our article on Phase 3).

The six lawsuits of 12 August

Eli Lilly announced six lawsuits in federal courts in California and Texas¹⁴. The defendants are Aesthetic Envy Cosmetic Centers (a California med spa), Striker Pharmacy (a compounding pharmacy), Astra LLC (Astra Peptides), Legendary Peptides, Texas Peptides and Lone Star Peptide Co.¹³⁵. According to an analysis by the law firm Frier Levitt, four are sellers that label their products "research use only", one is the med spa and one the pharmacy, which Lilly accuses of selling retatrutide to med spas and prescribers⁵.

In each case, Lilly seeks a permanent injunction barring the manufacture, marketing, distribution, dispensing or sale of any product containing or purporting to contain retatrutide, plus disgorgement of profits and attorney's fees⁵. Most of the suits rest on state unfair-competition and consumer-protection laws; the only false-advertising claim under the Lanham Act, the federal trademark law, targets the med spa, which according to Lilly promoted a product called "Triple G" on its website and social media⁵.

Lilly also accuses Lone Star of offering a patient-oriented dosage calculator on its website, and its CEO of addressing "you guys sitting at home" on TikTok⁴. At the time of reporting, Legendary Peptides had no comment and the other five companies had not responded³.

"Not practicing medicine"

Lilly's release aims squarely at med spas and wellness centers: it describes them as businesses posing as legitimate medical providers and states that they "are not practicing medicine; they are selling illegal drugs"¹³. Lilly says these products "could be fake, impure or mis-dosed"³.

The figure that matters most to physicians is the referrals. Lilly says it has reported more than 200 individuals and entities to the FDA, the Department of Justice, state attorneys general, law enforcement and professional licensing boards¹². It also asked platforms, payment processors and carriers to cut off the infrastructure of this trade¹.

What the FDA said about "Research Use Only"

The warning letter to Gram Peptides (California, 31 March 2026) shows the agency's reasoning. The company also sold retatrutide under the name "GLP-1-R Peptide", and its labeling said "Research Use Only" and "not intended for human consumption, medical use, or veterinary use"⁶. The FDA concluded that "evidence obtained from your website establishes that your products are intended to be drugs for human use"⁶.

What evidence? In that case, marketing language: the website said retatrutide "influences appetite suppression, insulin sensitivity, thermogenesis, and fat-oxidation models"⁶. And a less-known point: bacteriostatic water. Because it was sold alongside peptides that require reconstitution and injection, the FDA concluded it was intended for injection and therefore "is a drug"⁶. The letter classifies the products as unapproved new drugs and cites sections 301(d) and 505(a) of the Federal Food, Drug, and Cosmetic Act⁶.

On 24 August the FDA sent five more letters, to Peak Performance Peptides, Royal Peptides, NuScience Peptides, Peptide Partners and TXP Innovations (Tex Peptides); several included retatrutide⁸⁹. In the Royal Peptides letter, the agency also cited a "peptide guide" and "peptide calculator" sold alongside bacteriostatic water which, according to the FDA, together provide the means to prepare an injectable for human use⁷. On its page about unapproved GLP-1s, the FDA says products labeled "for research purposes" have been sold directly to consumers for human use with dosing instructions¹⁰.

Clinics in the crosshairs

The CBS News investigation of 8 June 2026, summarized by Drug Topics, identified more than 120 websites and more than 50 clinics in the US selling or promoting retatrutide; many were staffed by licensed physicians and nurse practitioners who, according to the report, argue the evidence justifies bypassing the regulatory timeline¹¹. A Minnesota physician quoted by CBS said: "I know that the FDA is going to approve this, and I thought, 'Why are we waiting?'"¹².

The FDA is explicit on three points that touch clinical practice: retatrutide cannot be used in compounding under federal law; it is not a component of any approved drug; and the agency has already warned telehealth companies for marketing it, distributors for selling it to compounders and outsourcing facilities for repackaging it¹⁰. Frier Levitt summarizes that, for a med spa, marketing or administering retatrutide-containing products is unlawful, and that marketing materials, dosing charts and in-clinic administration can be used as evidence of human use⁵.

What reaches the emergency room

Public Citizen counted, in the FDA's adverse event system, 10 retatrutide-related reports in 2025 (4 hospitalizations) and 26 in the first five months of 2026 (11 hospitalizations, 3 described as life-threatening); it also reported that of 14 companies that received FDA letters since 2024, 8 were still selling retatrutide in May 2026¹³.

Case reports are starting to appear. In Zurich, a woman in her mid-20s was admitted with refractory nausea and vomiting after four weekly injections of an unverified product reported to contain retatrutide, given in a wellness setting by a self-described life coach without medical qualification; she did not consider the injections to be medication, and the Naranjo score indicated probable causality¹⁶. In Edinburgh, a man with type 1 diabetes presented with ketonemia of 4.3 mmol/L and acute kidney injury after self-injecting retatrutide bought online; he also had shigellosis, so the authors could not establish causality¹⁷. A review groups it among "biohacking" drugs lacking an established human safety profile¹⁸.

Not just the US

On 24 July 2026, the UK MHRA warned that retatrutide is not authorised in the UK, that anyone selling it is doing so illegally and that there is no guarantee such products even contain it¹⁹. In May it had dismantled a facility that, according to the agency, manufactured and distributed unlicensed weight-loss medicines including retatrutide: around 12,000 doses seized and two arrests²⁰. In Colombia, INVIMA issued an alert over the illicit sale of injectable peptide solutions without sanitary registration²¹.

A note on the efficacy figures

Retatrutide's advocates often cite −28.3% body weight at 80 weeks with 12 mg in TRIUMPH-1¹¹. That is correct, but it is the efficacy estimand (participants who stayed on treatment); with the treatment-regimen estimand, which includes those who discontinued, the figure is −25.0% versus −3.9% with placebo¹⁴¹⁵. 11.3% of patients on 12 mg discontinued due to adverse events, versus 4.9% on placebo¹⁴.